Rick Wise, an analyst from Stifel Nicolaus, maintained the Buy rating on Becton Dickinson (BDX – Research Report). The associated price target remains the same with $280.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Rick Wise has given his Buy rating due to a combination of factors that highlight Becton Dickinson’s strategic moves and promising prospects. The company’s announcement of a Diagnostics business separation, expected to occur in fiscal 2026, is seen as a significant step forward in its ongoing transformation. This separation is anticipated to leave Becton Dickinson with a strong, pure-play MedTech business valued at approximately $18 billion, characterized by a robust growth trajectory and improving margins.
Additionally, the separation aligns with Becton Dickinson’s focus on optimizing their innovation investments, potentially unlocking value that could lead to new opportunities in faster-growing MedTech adjacent markets. Despite some concerns in the market about costs and financial specifics related to the separation, Wise believes the company’s disciplined portfolio management and past performance in enhancing growth and margins through acquisitions support a positive outlook. The strong start to fiscal 2025 with above-consensus results further reinforces the potential for continued quarterly outperformance, positioning Becton Dickinson favorably for the future.
In another report released today, Barclays also maintained a Buy rating on the stock with a $278.00 price target.
BDX’s price has also changed slightly for the past six months – from $235.510 to $227.210, which is a -3.52% drop .